Daito Pharmaceutical Co., Ltd.
Stock Price Chart
2026/10/09 12:26 UpdatedPrice Trend
2026/10/09 12:26 UpdatedPrice & Trading Details
2026/10/09 12:26 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/10/01Shareholder Composition
Updated 2026/10/01Top Mutual Funds / ETFs
Updated 2026/10/01Major Holders
Updated 2026/10/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
373.4K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
248.2K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
217.8K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
197.1K | 0.00% | |
|
Dimensional ETF Trust-Dimensional International Small Cap Value ETF
|
164.5K | +8.80% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
146.7K | -5.23% |
Dividend History
Updated 2026/10/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥20 | -46.7% |
| 2025 | ¥38 | +15.4% |
| 2024 | ¥33 | +13.5% |
| 2023 | ¥29 | -3.1% |
| 2022 | ¥30 | - |
Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥45,101M | ¥46,895M | ¥50,643M | ¥50,650M |
| Gross Profit | ¥10,331M | ¥9,839M | ¥8,637M | ¥9,897M |
| Operating Income | ¥5,208M | ¥3,894M | ¥2,620M | ¥3,637M |
| Pretax Income | ¥5,088M | ¥4,259M | ¥3,081M | ¥4,195M |
| Net Income | ¥3,600M | ¥3,295M | ¥1,908M | ¥3,161M |
| EPS | ¥113.71 | ¥105.00 | ¥62.74 | ¥107.49 |
| Operating Margin | 11.55% | 8.30% | 5.17% | 7.18% |
| Balance Sheet | ||||
| Total Assets | ¥70,552M | ¥77,708M | ¥78,004M | ¥73,291M |
| Total Equity | ¥50,672M | ¥52,068M | ¥52,003M | ¥52,891M |
| Total Liabilities | ¥19,880M | ¥25,640M | ¥26,001M | ¥20,400M |
| Cash | ¥3,607M | ¥2,727M | ¥2,207M | ¥954M |
| Interest-bearing Debt | ¥4,889M | ¥8,719M | ¥11,885M | ¥9,294M |
| Equity Ratio | 71.82% | 67.00% | 66.67% | 72.17% |
| D/E Ratio | 0.10 | 0.17 | 0.23 | 0.18 |
| Cash Flow | ||||
| Operating CF | ¥4,155M | ¥5,182M | ¥5,897M | ¥9,377M |
| Investing CF | -¥5,566M | -¥5,930M | -¥7,365M | -¥4,388M |
| Financing CF | ¥616M | -¥183M | ¥1,002M | -¥6,289M |
| Free CF | -¥1,401M | -¥1,094M | -¥1,198M | ¥4,160M |
| Efficiency | ||||
| ROE | 7.10% | 6.33% | 3.67% | 5.98% |
| ROA | 5.10% | 4.24% | 2.45% | 4.31% |
Latest IR Information
-
Daito Pharmaceutical Co.,Ltd. to Establish Jointly Funded Company for Succession of Kyorin Pharmaceutical's Generic Drug Business and Conclude Share Transfer Agreement
A co-creation organization will be established with at least three parties to succeed Kyorin Pharmaceutical's generic drug business. Daito Pharmaceutical Co.,Ltd. will hold 49.1%, Meiji Seika Pharma 36.0%, and DBJ 14.9%. The co-creation organization is scheduled to be established in...
Read more -
Financial Results Explanation Document
For the fiscal year ending May 2026, consolidated sales are forecasted to be 50,650 million yen (YoY +0.0%), with operating income at 3,637 million yen (up 38.8%). Increased research and development expenses and capital investments are expected to improve profit...
Read more -
Notice of Completion of Share Buyback｜July 2026
Diet Stock Corporation completed its share buyback implemented on July 10, 2026, acquiring 484,000 shares for a total of 600 million yen. This is part of its capital policy aimed at shareholder returns and enhancing capital efficiency.
Read more -
Notice of Change of Representative Director, Appointment of New Director Candidates, and Change of Executive Officers
Announcement of the appointment of three new director candidates and changes to directors and executive officers. Resignation of the representative director with a view to becoming chairman, new appointments and transfers of executive officers, and the establishment of a new...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,400
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Daito Pharmaceutical Co.,Ltd. engages in the manufacture and sale of pharmaceutical products in Japan and internationally. It offers active pharmaceutical ingredients for generic drugs; develops and manufactures generic and over-the-counter drugs; and contract manufacturing services for ethical drugs. The company is also involved in the wholesale of pharmaceutical and veterinary medicine. It exports its products to the United States, as well as European and Asian countries. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
